Press Release
Fuld & Company  - The Leader in Competitive Intelligence
News
MainTitle

Fuld & Company Announces Appointment of MIT Fellow to Head Pharmaceutical Team's Strategic Gaming and Consulting Services

CAMBRIDGE, Mass., Dec 16, 2008 /PRNewswire via COMTEX/ -- Fuld & Company today announced that Wayne Rosenkrans, Ph.D., will join the Company as vice president consulting, specializing in strategic gaming for the pharmaceutical and healthcare industries.

"We are excited to have Dr. Rosenkrans join the Fuld team," said Leonard Fuld, president. "His extensive accomplishment in the global pharmaceutical industry; government and academia -- coupled with his involvement on the cutting edge of personalized medicine -- makes him an extraordinary asset for our clients."

Fuld & Company's Pharmaceuticals Practice provides all levels of competitive support from research to consulting. The firm has serviced over 100 biotech, pharmaceutical and diagnostics/device companies for training, custom research, and systems consulting needs. Fuld assesses new product progress from early-stage development to product launch, technology partnerships between biotech and big pharma, as well as changing global technologies, regulations, and markets. The firm has researched over 60 different therapeutic categories worldwide.

Rosenkrans is a Distinguished Fellow at the Center for Biomedical Innovation at MIT working on healthcare strategy and policy issues related to science and medicine. He is also Chairman, President and a member of the board of directors of the Personalized Medicine Coalition, a Washington DC-based organization working with government and other agencies on evolving healthcare policy for Personalized Healthcare. He is also Chief Applications Officer for SciTech Strategies, focusing on scientific competency and capacity development for academia and industry.

Previously, Rosenkrans served as Director of External Relations for the Personalized Healthcare Team and Evidence-based Medicine (EBM) at AstraZeneca where he had responsibility for long-range external relations strategy and policy development. He has presented at numerous forums on aspects of personalized healthcare, evidence-based medicine, new development paradigms, and strategy development.

Rosenkrans holds an S.B. in Biology from MIT, a Ph.D. in Cell and Molecular Biology from Boston University, and received post-doctoral training in Cancer and Radiation Biology at the University of Rochester.

Fuld & Company, based in Cambridge, Mass., with offices in London, is the world's preeminent research and consulting firm in the field of competitive intelligence. Founded by Leonard Fuld, a pioneer and recognized leading authority in the field, Fuld & Company is a full-service competitive intelligence firm, providing research and analysis, strategic gaming, intelligence process consulting, and training to help clients understand the external competitive environment. The firm's mission is to help clients improve their performance by making better decisions through the application of solid intelligence on their markets and competitors. Additional information can be found at: www.fuld.com.